August 3, 2021
The psychedelics space is booming. Over the past year, startups focused on turning psychedelic compounds into approved medicines have raised hundreds of millions of dollars from private investors and dozens have gone public. Research on compounds like psilocybin, the active compound found in magic mushrooms, and MDMA is resurfacing after years of neglect amid the war on drugs.
Full articleAugust 3, 2021
House Committee Suggests That NIH Study Psychedelics for Treating Mental Health Issues. Oregon Psilocybin Advisory Board’s First Report. Pennsylvania’s Attempt to Study Psilocybin-assisted Therapy. And much more. Join Ritika Dubey for the latest in developments on psychedelic decriminalization and research.
Full articleJuly 5, 2021
A study by researchers at Yale University showed that Psilocybin can remodel connections in the mouse brain. This might explain psilocybin’s enduring antidepressant effects. "We not only saw a 10% increase in the number of neuronal connections, but also they were on average about 10% larger, so the connections were stronger as well.”
Full articleJune 23, 2021
Psychedelics are following cannabis into the mainstream of medicine, with Texas and Connecticut enacting laws this month allowing research into how psilocybin, the active ingredient in “magic mushrooms” might help people with post-traumatic stress disorder. Gov. Greg Abbott (R-Texas) on June 18 allowed a bill (H.B. 1802) authorizing the study of psilocybin to become law without his signature.
Full articleJune 22, 2021
Recently, psychedelic drugs have once again taken popular culture by storm. From the psychedelic startup companies newly forming on Wall Street to a recent New York Timesarticle that claims "psychedelic drugs are closer to medicinal use," it seems that there is a renewed media and medical interest in acid (LSD), mushrooms (psilocybin), ecstasy (MDMA), ayahuasca, DMT (dimethyltryptamine), and ketamine.
Full article